Cargando…

Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations

BACKGROUND: Women with inherited mutations in the BRCA1 or BRCA2 genes have increased lifetime risks for developing breast and/or ovarian cancer and may develop these cancers around the age of 30 years. Therefore, prevention of breast and ovarian cancer in these women may need to start relatively ea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hallsson, Lára R., Sroczynski, Gaby, Engel, Jutta, Siebert, Uwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294312/ https://www.ncbi.nlm.nih.gov/pubmed/37365514 http://dx.doi.org/10.1186/s12885-023-10956-6

Ejemplares similares

Cost-Effectiveness of Early Detection and Prevention Strategies for Endometrial Cancer—A Systematic Review
por: Sroczynski, Gaby, et al.
Publicado: (2020)

Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany
por: Sroczynski, Gaby, et al.
Publicado: (2010)

Decision-analytic modeling for early health technology assessment of medical devices – a scoping review
por: Conrads-Frank, Annette, et al.
Publicado: (2022)

Vergleich der Effektivität von multiplen dynamischen Behandlungsstrategien unter Nutzung der Target-Trial-Emulierung: Kontrafaktischer Ansatz zur Kausalinferenz aus Real-World-Daten
por: Kuehne, Felicitas, et al.
Publicado: (2023)

Antiviral combination therapy with interferon/peginterferon plus ribavirin for patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Agency for Health Technology Assessment
por: Siebert, Uwe, et al.
Publicado: (2003)

Long-Term Effectiveness and Cost Effectiveness of Multiple Myeloma Treatment Strategies for Elderly Transplant-Ineligible Patients in Serbia
por: Vukićević, Đurđa, et al.
Publicado: (2020)

Assessment of effectiveness and cost-effectiveness of HPV testing in primary screening for cervical
por: Mittendorf, Thomas, et al.
Publicado: (2007)

Estimation of Input Costs for a Markov Model in a German Health Economic Evaluation of Newer Antidepressants
por: Seidl, Astrid, et al.
Publicado: (2018)

Pharmacogenomics Bias - Systematic distortion of study results by genetic heterogeneity
por: Siebert, Uwe, et al.
Publicado: (2008)

Using decision-analytic modelling to transfer international evidence from health technology assessment to the context of the German health care system
por: Siebert, Uwe
Publicado: (2005)

Causal evidence in health decision making: methodological approaches of causal inference and health decision science
por: Kühne, Felicitas, et al.
Publicado: (2022)

Cost-effective BRCA Testing in Advanced Ovarian Cancer
por: Kim, Myungshin
Publicado: (2023)

Evaluating the effects of a risk-adapted screening program for familial colorectal cancer in individuals between 25 and 50 years of age: study protocol for the prospective population-based intervention study FARKOR
por: Hoffmann, Sabine, et al.
Publicado: (2020)

Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria
por: Jahn, Beate, et al.
Publicado: (2019)

HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality
por: Mühlberger, Nikolai, et al.
Publicado: (2009)

Haplotype analysis in German families with recurrent BRCA1 and BRCA2 mutations
por: Wappenschmidt, B, et al.
Publicado: (2001)

Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online
por: Jahn, Beate, et al.
Publicado: (2017)

P16 COVID-19 Vaccination Strategies Considering a Vaccine Adapted to a New Variant of Concern: A Decision-Analytic Modeling Study
por: Jahn, B., et al.
Publicado: (2022)

Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision
por: Lewis, Kelsey E., et al.
Publicado: (2018)

Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review
por: Krassuski, Lisa, et al.
Publicado: (2019)

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer
por: Eccleston, Anthony, et al.
Publicado: (2017)

Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome
por: Ashour, Mohamed, et al.
Publicado: (2019)

POSA172 How to Optimize COVID-19 Vaccination Considering Limited Vaccination Capacities: A Decision-Analytic Framework and Modeling Study
por: Jahn, B, et al.
Publicado: (2022)

Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer – Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?
por: Ataseven, Beyhan, et al.
Publicado: (2020)

Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness
por: de Bock, G H, et al.
Publicado: (2013)

BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
por: Manchana, Tarinee, et al.
Publicado: (2020)

The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status
por: C.E, Drechsel Katja, et al.
Publicado: (2022)

Cost–utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland
por: Bommer, Claudine, et al.
Publicado: (2021)

The Role of decision-analytic modelling in German health technology assessments
por: Kuhlmann, Alexander, et al.
Publicado: (2015)

Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
por: Birkbak, Nicolai Juul, et al.
Publicado: (2013)

BRCA mutations in the manifestation and treatment of ovarian cancer
por: Pan, Zimin, et al.
Publicado: (2017)

A Cost Decision Model Supporting Treatment Strategy Selection in BRCA1/2 Mutation Carriers in Breast Cancer
por: Carbonara, Nunzia, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Germline and Somatic BRCA Testing in Patients With Advanced Ovarian Cancer
por: Jang, Jaehyeok, et al.
Publicado: (2023)

Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
por: Arakelyan, Arsen, et al.
Publicado: (2021)

Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation
por: Ramos, Marcelo Cristiano de Azevedo, et al.
Publicado: (2018)

An iterative algorithm for optimizing COVID-19 vaccination strategies considering unknown supply
por: Bicher, Martin, et al.
Publicado: (2022)

Application of Decision-Analytic Models in Personalized Medicine for CML Treatment Decisions Made by Payers, Providers, and Patients
por: Saverno, Kim R., et al.
Publicado: (2012)

Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
por: Maistro, Simone, et al.
Publicado: (2016)

BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
por: Savanevich, Alena, et al.
Publicado: (2021)

BRCA1 founder mutations and ovarian cancer in Belarus
por: Savanevich, A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ihi6ii8a71j8ao6fjslus73vs2